Skip to main content

Table 2 Information on prescribing disease-modifying anti-rheumatic drugs

From: Primary care physicians' perspectives towards managing rheumatoid arthritis: room for improvement

 

Total

DMARD prescribers a

DMARD non-prescribers

 

n= 266 b

n= 217

n= 49

Initial prescription, continuation, or both

   

   First only

 

20 (9%)

 

   Continuation only

 

98 (45%)

 

   Both

 

99 (46%)

 

Prescribed DMARDs

   

   Methotrexate

 

195 (90%)

 

   Hydroxychloroquine

 

171 (79%)

 

   Sulfasalazine

 

135 (62%)

 

   Leflunomide

 

43 (20%)

 

   Gold

 

35 (16%)

 

   Azathioprine

 

54 (25%)

 

   Cyclosporine

 

32 (15%)

 

   Abatacept

 

8 (4%)

 

   Etanercept

 

64 (29%)

 

   Infliximab

 

56 (26%)

 

   Rituximab

 

20 (9%)

 

   Adalimumab

 

43 (20%)

 

   Certolizumab pegol

 

2 (1%)

 

   Golimumab

 

1 (0%)

 

Type of DMARDs prescribeda

   

   Biologic and non-biologic DMARDs

 

96 (44%)

 

   Non-biologic DMARDs only

 

118 (54%)

 

   Biologic DMARDs only

 

2 (1%)

 

Factors that make patients inappropriate candidates for DMARDs

   

   No need (well controlled without DMARDs)

131 (49%)

110 (51%)

21 (43%)

   Too sick to take a DMARD

92 (35%)

78 (36%)

14 (29%)

   Side effects of DMARDs too problematic

148 (56%)

128 (59%)

20 (41%)

   Drug interactions

83 (31%)

74 (34%)

9 (18%)

   Drug cost and monitoring are too high

142 (55%)

115 (53%)

27 (55%)

   Cannot get laboratory monitoring

20 (8%)

17 (8%)

3 (6%)

Best time to initiate DMARDs

   

   After a trial of NSAIDs or steroids

92 (35%)

75 (35%)

17 (35%)

   Within the first 6 months of diagnosis

159 (60%)

132 (61%)

27 (55%)

   At least 6 months after diagnosis

13 (5%)

9 (4%)

4 (8%)

Comfort level starting a DMARDc

   

   Very comfortable

23 (9%)

23 (11%)

0 (0%)

   Somewhat comfortable

79 (30%)

73 (34%)

6 (12%)

   Somewhat uncomfortable

112 (42%)

89 (41%)

23 (47%)

   Very uncomfortable

50 (19%)

30 (14%)

20 (41%)

Comfort level continuing a DMARDd

   

   Very comfortable

75 (28%)

71 (33%)

4 (8%)

   Somewhat comfortable

130 (49%)

107 (50%)

23 (47%)

   Somewhat uncomfortable

54 (20%)

37 (17%)

17 (35%)

   Very uncomfortable

6 (2%)

1 (0%)

5 (10%)

  1. aOne prescriber did not fill in types of disease-modifying anti-rheumatic drugs (DMARDs). bOne missing response. cThree missing responses. dTwo missing responses. NSAID, non-steroidal anti-inflammatory drug.